Hims & Hers is shutting down Apostrophe, the skincare company it acquired in 2021, after a tumultuous month for the public ...

Founded in 2018, Defiance is at the forefront of ETF innovation. Defiance is a leading ETF issuer specializing in thematic, ...

Hims & Hers (NYSE: HIMS) is taking investors on a roller-coaster ride in 2025. Where to invest $1,000 right now? Our analyst ...

After years of weight loss drug shortages, the FDA is saying there’s now an adequate supply for most medications and they ...

The FDA's updated enforcement timelines provide a clearer regulatory framework for the compounding of semaglutide, a medication used in treatments that are part of Hims & Hers' product lineup.

We recently compiled a list of the 10 Best Skincare Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Hims & Hers Health is now reasonably valued after ... The peptide facilities "will be used to boost its supply chain and demand for its medicines," according to the news article on Seeking Alpha ...

We have used the stock’s Revenue Growth Rate (year ... beating its benchmark by 218 percentage points (see more details here). Hims & Hers Health, Inc. (NYSE:HIMS) is a multi-specialty ...

Believe it or not, there's something worse than male pattern baldness. It's depression, plunging libido and shrinking ...

Hims & Hers (NYSE: HIMS ... stock's decline and why investors need to take a long-term view. *Stock prices used were end-of-day prices of March 7, 2025. The video was published on March 10 ...

To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...

This funding request comes in response to a recent US executive order that has impacted global health funding, including support for HIV programmes in Kenya.